ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

ÌÇÐÄ´«Ã½

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nature medicine Morschhauser, F., Dahiya, S., Palomba, M. L., Martin Garcia-Sancho, A., Reguera Ortega, J. L., Kuruvilla, J., Jäger, U., Cartron, G., Izutsu, K., Dreyling, M., Kahl, B., Ghesquieres, H., Ardeshna, K., Goto, H., Barbui, A. M., Abramson, J. S., Borchmann, P., Fleury, I., Mielke, S., Skarbnik, A., de Vos, S., Kamdar, M., Karmali, R., Viardot, A., Farazi, T., Fasan, O., Lymp, J., Vedal, M., Nishii, R., Avilion, A., Papuga, J., Kumar, J., Nastoupil, L. J. 2024

Abstract

An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24?months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB CAR T cell product. The phase 2 TRANSCEND FL study evaluated liso-cel in patients with R/R FL, including 2L patients who all had POD24 from diagnosis after treatment with anti-CD20 antibody and alkylator =6?months of FL diagnosis and/or met modified Groupe d'Etude des Lymphomes Folliculaires criteria. Primary/key secondary endpoints were independent review committee-assessed overall response rate (ORR)/complete response (CR) rate. At data cutoff, 130 patients had received liso-cel (median follow-up, 18.9?months). Primary/key secondary endpoints were met. In third-line or later FL (n?=?101), ORR was 97% (95% confidence interval (CI): 91.6?99.4), and CR rate was 94% (95% CI: 87.5?97.8). In 2L FL (n?=?23), ORR was 96% (95% CI: 78.1?99.9); all responders achieved CR. Cytokine release syndrome occurred in 58% of patients (grade =3, 1%); neurological events occurred in 15% of patients (grade =3, 2%). Liso-cel demonstrated efficacy and safety in patients with R/R FL, including high-risk 2L FL. ClinicalTrials.gov identifier: NCT04245839 .

View details for

View details for

View details for